These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 16054421)

  • 1. New approaches to reverse resistance to hormonal therapy in human breast cancer.
    Weinberg OK; Marquez-Garban DC; Pietras RJ
    Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing the efficacy of hormonal agents with selected targeted agents.
    Johnston SR
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J; Sommer A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
    Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
    Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
    Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
    J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
    Prat A; Baselga J
    Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials update: Medical management of advanced breast cancer.
    Major MA
    Cancer Nurs; 2003 Dec; 26(6 Suppl):10S-15S. PubMed ID: 15025407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of endocrine adjuvant therapy for early breast cancer.
    Lønning PE
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S19-30. PubMed ID: 20374026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
    Johnston SR; Head J; Pancholi S; Detre S; Martin LA; Smith IE; Dowsett M
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):524S-32S. PubMed ID: 12538510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal therapy for advanced breast cancer.
    Rugo HS
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
    Schiff R; Massarweh S; Shou J; Osborne CK
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):447S-54S. PubMed ID: 12538499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatase inhibitors: future directions.
    Osborne CK; Schiff R
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):183-7. PubMed ID: 16019204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine therapy of advanced disease: analysis and implications of the existing data.
    Pritchard KI
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):460S-7S. PubMed ID: 12538501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.
    Johnston SR
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1061s-1068s. PubMed ID: 16467125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.